Status:
NOT_YET_RECRUITING
Cardiovascular Performance and Exercise Response in Patients With Persistent or Permanent Atrial Fibrillation and Heart Failure Pre and Post Cardioversion or Pace and Ablate
Lead Sponsor:
Habib Khan
Conditions:
Atrial Fibrillation (AF)
Heart Failure - NYHA II - IV
Eligibility:
All Genders
18+ years
Brief Summary
Heart Failure (HF) and Atrial Fibrillation (AF) are two conditions that commonly occur together. Clinical guidelines consider a resting heart rate of 100-110 beats per minute (bpm) acceptable for pati...
Eligibility Criteria
Inclusion
- Age ≥ 18
- Persistent or Permanent Atrial Fibrillation
- HF - NYHA class II-IVA despite guideline-direct medical therapy
- Rate controlled
- Able to perform stress test
- Scheduled for clinical P\&A OR cardioversion
Exclusion
- Creatinine \>180 μmol/L or eGFR \<30 mL/min/1.73 m2
- Significant valvular heart disease: Moderate to severe tricuspid regurgitation, mitral regurgitation, mitral stenosis, aortic regurgitation, aortic stenosis
- Patients who have had a TAVI, valvular surgery, or CABG within 3 months of enrolment
- Right ventricular systolic pressure \>50mmHg
- Existing pacemaker
- In sinus rhythm
- Predictable vasovagal syncope to pain and sight of blood
Key Trial Info
Start Date :
October 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2026
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT07205679
Start Date
October 1 2025
End Date
July 1 2026
Last Update
October 3 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.